open access

Ahead of print
Original research article
Submitted: 2022-04-08
Accepted: 2022-04-17
Published online: 2022-07-25
Get Citation

Characteristics of COVID-19 in pediatric patients with hematological malignancies

Olga Troyanovska12, Olga Dorosh23, Halyna Lytvyn4, Iryna Tsymbalyuk2, Oxana Vorobel2, Olena Stepanyuk2, Hrystyna Bodak2, Olena Kozlova21, Mariya Stasiv4, Nata Basiv4
DOI: 10.5603/AHP.a2022.0035
Affiliations
  1. Department of Pediatrics N2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
  2. Western Ukrainian Specialized Children’s Medical Centre, Lviv, Ukraine
  3. Department of Pediatrics and Neonatology FPGE, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
  4. Department of Pediatric Infectious Diseases, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

open access

Ahead of print
ORIGINAL RESEARCH ARTICLE
Submitted: 2022-04-08
Accepted: 2022-04-17
Published online: 2022-07-25

Abstract

Introduction: As more data is collected, hematologists will be able to gain more insight into the impact of coronavirus disease 2019 (COVID-19) on pediatric patients with hematological malignancies.

Material and methods: We analysed 21 cases of COVID-19 in pediatric patients with onco-hematological diseases treated in the Western Ukrainian Pediatric Medical Center from March 2020 through May 2021. The majority of patients (71.4%) were diagnosed with acute lymphoblastic leukemia. All patients from the analyzed cohort had an asymptomatic, mild or moderate course of coronavirus-19 infection. The most common symptoms of COVID-19 were fever, cough, gastrointestinal symptoms, and dermatitis. Severe severe acute respiratory syndrome coronavirus 2 increased the risk of liver toxicity and venous thrombosis.

Results and conclusion: Our analysis showed that pediatric patients with hematological malignancies need the same treatment approach for COVID-19 as for other infective complications.

Abstract

Introduction: As more data is collected, hematologists will be able to gain more insight into the impact of coronavirus disease 2019 (COVID-19) on pediatric patients with hematological malignancies.

Material and methods: We analysed 21 cases of COVID-19 in pediatric patients with onco-hematological diseases treated in the Western Ukrainian Pediatric Medical Center from March 2020 through May 2021. The majority of patients (71.4%) were diagnosed with acute lymphoblastic leukemia. All patients from the analyzed cohort had an asymptomatic, mild or moderate course of coronavirus-19 infection. The most common symptoms of COVID-19 were fever, cough, gastrointestinal symptoms, and dermatitis. Severe severe acute respiratory syndrome coronavirus 2 increased the risk of liver toxicity and venous thrombosis.

Results and conclusion: Our analysis showed that pediatric patients with hematological malignancies need the same treatment approach for COVID-19 as for other infective complications.

Get Citation

Keywords

COVID-19, haematological malignancies, immunosuppression, paediatric patients

About this article
Title

Characteristics of COVID-19 in pediatric patients with hematological malignancies

Journal

Acta Haematologica Polonica

Issue

Ahead of print

Article type

Original research article

Published online

2022-07-25

Page views

16

Article views/downloads

11

DOI

10.5603/AHP.a2022.0035

Keywords

COVID-19
haematological malignancies
immunosuppression
paediatric patients

Authors

Olga Troyanovska
Olga Dorosh
Halyna Lytvyn
Iryna Tsymbalyuk
Oxana Vorobel
Olena Stepanyuk
Hrystyna Bodak
Olena Kozlova
Mariya Stasiv
Nata Basiv

References (13)
  1. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020; 382(17): 1663–1665.
  2. André N, Rouger-Gaudichon J, Brethon B, et al. COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: High risk of severe forms? Pediatr Blood Cancer. 2020; 67(7): e28392.
  3. Mercolini F, Cesaro S. COVID-19 in children and adolescents: characteristics and specificities in immunocompetent and oncohematological patients. Mediterr J Hematol Infect Dis. 2022; 14(1): e2022009.
  4. Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020; 11: 1446.
  5. Cron RQ, Caricchio R, Chatham WW. Calming the cytokine storm in COVID-19. Nature Medicine. 2021; 27(10): 1674–1675.
  6. Yasuhara J, Watanabe K, Takagi H, et al. COVID-19 and multisystem inflammatory syndrome in children: a systematic review and meta-analysis. Pediatr Pulmonol. 2021; 56(5): 837–848.
  7. Schoot TS, Kerckhoffs APM, Hilbrands LB, et al. Immunosuppressive drugs and COVID-19: a review. Front Pharmacol. 2020; 11: 1333.
  8. Valencia-Sanchez C, Wingerchuk DM. A fine balance: immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19. Mult Scler Relat Disord. 2020; 42: 102182.
  9. Hrusak O, Kalina T, Wolf J, et al. Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. Eur J Cancer. 2020; 132: 11–16.
  10. Hammad M, Shalaby L, Sidhom I, et al. Management and outcome of coronavirus disease 2019 (COVID-19) in pediatric cancer patients: a single centre experience from a developing country. Clin Lymphoma Myeloma Leuk. 2021; 21(11): e853–e864.
  11. Millen GC, Arnold R, Cazier JB, et al. Severity of COVID-19 in children with cancer: report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project. Br J Cancer. 2021; 124(4): 754–759.
  12. Diorio C, McNerney KO, Lambert M, et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020; 4(23): 6051–6063.
  13. Taub JW, Ge Y, Xavier AC. COVID-19 and childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020; 67(7): e28400.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl